Healthcare >> CEO Interviews >> November 1, 2002
DANIEL L. KORPOLINSKI is President and Chief Executive Officer of
Stressgen. Mr. Korpolinski has considerable experience in the US
public markets and brings to Stressgen a strong track record of
successful corporate partnering and managing late stage
development companies. He has held a number of senior executive
positions within the pharmaceutical industry. From September 1998
to December 1999, Mr. Korpolinski was President and CEO of Copley
Pharmaceutical Inc., a generic pharmaceutical company. Mr.
Korpolinski managed the sale of Copley Pharmaceutical to Teva
Pharmaceutical for the Board and the Shareholders. Between
1991-1996, Mr. Korpolinski served as the President and CEO of
CoCensys Inc., a biotechnology company specializing in the
development of therapeutics for the central nervous system.
During his tenure at CoCensys, he led the company's IPO on NASDAQ
and put in place six partnerships with major pharmaceutical
companies. From 1988-1991, Mr. Korpolinski was President of Adria
Laboratories North America, an oncology company with US sales of
over $250 million. Mr. Korpolinski started his career in the
pharmaceutical industry with the Upjohn Company spending over 24
years culminating in several corporate positions including
Executive Director of one of its Pharmaceutical Business Groups
and subsequently its Consumer Products Group. Profile
Biotechnologies?
Mr. Korpolinski: The company is over 11 years old; we started in
1990. It had started out as a company looking at heat
